The “Golden Hour” and Acute Brain Ischemia: Presenting Features and Lytic Therapy in >30 000 Patients Arriving Within 60 Minutes of Stroke Onset

Background and Purpose— The benefit of intravenous thrombolytic therapy in acute brain ischemia is strongly time dependent. Methods— The Get With the Guidelines–Stroke database was analyzed to characterize ischemic stroke patients arriving at hospital Emergency Departments within 60 minutes of the last known well time from April 1, 2003, to December 30, 2007. Results— During the 4.75-year study period, among 253 148 ischemic stroke patients arriving directly by ambulance or private vehicle at 905 hospital Emergency Departments, 106 924 (42.2%) had documented, exact last known well times. Onset to door time was ≤60 minutes in 30 220 (28.3%), 61 to 180 minutes in 33 858 (31.7%), and >180 minutes in 42 846 (40.1%). Features most strongly distinguishing the patients arriving at ≤60, 61 to 180, and >180 minutes were greater stroke severity (median National Institutes of Health Stroke Scale score, 8.0 vs 6.0 vs 4.0, P<0.0001) and more frequent arrival by ambulance (79.0%. vs 72.2% vs 55.0%, P<0.0001). Compared with patients arriving at 61 to 180 minute, “golden hour” patients received intravenous thrombolytic therapy more frequently (27.1% vs 12.9%; odds ratio=2.51; 95% CI, 2.41–2.61; P<0.0001), but door-to-needle time was longer (mean, 90.6 vs 76.7 minutes, P<0.0001). A door-to-needle time of ≤60 minutes was achieved in 18.3% of golden hour patients. Conclusions— At Get With the Guidelines-Stroke hospital Emergency Departments, more than one quarter of patients with documented onset time and at least one eighth of all ischemic stroke patients arrived within 1 hour of onset, where they received thrombolytic therapy more frequently but more slowly than late arrivers. These findings support public health initiates to increase early presentation and shorten door-to-needle times in patients arriving within the golden hour.

[1]  V. Thijs,et al.  Obstacles to the use of intravenous tissue plasminogen activator for acute ischemic stroke. Is time the only barrier? , 2007, Acta neurologica Belgica.

[2]  A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. , 1997, Stroke.

[3]  Li Liang,et al.  Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2009, Circulation.

[4]  Jeffrey L Saver,et al.  Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. , 2009, Stroke.

[5]  W. Rosamond,et al.  A Comprehensive Review of Prehospital and In-Hospital Delay Times in Acute Stroke Care , 2009, International journal of stroke : official journal of the International Stroke Society.

[6]  California Acute Stroke Pilot Registry Investigators Prioritizing interventions to improve rates of thrombolysis for ischemic stroke , 2005 .

[7]  C. Janson,et al.  Essay: White daisies on my mind (Requiem for an Alzheimer patient) , 2005, Neurology.

[8]  Bernadette Boden-Albala,et al.  Use of thrombolysis in acute ischemic stroke: analysis of the Nationwide Inpatient Sample 1999 to 2004. , 2007, Annals of emergency medicine.

[9]  Xin Tong,et al.  Paul Coverdell National Acute Stroke Registry Surveillance - four states, 2005-2007. , 2009, Morbidity and mortality weekly report. Surveillance summaries.

[10]  U. Bauer,et al.  [Centers for Disease Control and Prevention (CDC)]. , 2000, Annales de dermatologie et de venereologie.

[11]  Michael D. Hill,et al.  Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study , 2005, Canadian Medical Association Journal.

[12]  Peter Moyer,et al.  Recommendations for the Establishment of Stroke Systems of Care: Recommendations From the American Stroke Association’s Task Force on the Development of Stroke Systems , 2005, Circulation.

[13]  Matthew W Kreuter,et al.  Tailored and targeted health communication: strategies for enhancing information relevance. , 2003, American journal of health behavior.

[14]  Eric E. Smith,et al.  Quality of Care in Women With Ischemic Stroke in the GWTG Program , 2009, Stroke.

[15]  Mark Bayley,et al.  Canadian best practice recommendations for stroke care (updated 2008) , 2008, Canadian Medical Association Journal.

[16]  Robert A. Zimmerman,et al.  Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. , 1990, Stroke.

[17]  L. Thomassen,et al.  Intravenous thrombolysis for ischaemic stroke: short delays and high community-based treatment rates after organisational changes in a previously inexperienced centre , 2009, Emergency Medicine Journal.

[18]  J. Saver Time Is Brain—Quantified , 2006, Stroke.

[19]  M. Budoff,et al.  National Institute of Neurological Disorders and Stroke , 2008 .

[20]  Pamela W Duncan,et al.  Ethnic Disparities in Stroke: Epidemiology, Acute Care, and Postacute Outcomes , 2005, Stroke.

[21]  L. Schwamm,et al.  Hospital treatment of patients with ischemic stroke or transient ischemic attack using the "Get With The Guidelines" program. , 2008, Archives of internal medicine.

[22]  G. Albers,et al.  Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. , 2000, JAMA.

[23]  Werner Hacke,et al.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.

[24]  Stanley Tuhrim,et al.  Editorial comment--ethnic disparities in stroke: epidemiology, acute care, and postacute outcomes. , 2004, Stroke.

[25]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[26]  Maarten Schrooten,et al.  Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale , 2009, Stroke.

[27]  S. Y. Kim,et al.  Pre‐hospital notification reduced the door‐to‐needle time for iv t‐PA in acute ischaemic stroke , 2009, European journal of neurology.